Condition: Coronavirus · Respiratory Infection · COVID · Sponsor: BioFire Defense LLC
The Biomedical Advanced Research and Development Authority (BARDA) has contracted BioFire Defense (BFDf) to develop the BioFire Emerging Coronavirus (ECoV) Panel, a nucleic acid test capable of detecting coronaviruses from nasopharyngeal swab (NPS) in transport medium. This study aims to evaluate the diagnostic accuracy of the assays comprising the BioFire ECoV Panel. It is hypothesized that the BioFire ECoV Panel assays will be highly sensitive and specific for the detection of the coronaviruses included on the panel.
This description comes directly from the study's public registry record.
Brittany C Collins, PhD · 801-262-3592 · brittany.collins@biofiredefense.com
David Rabiger, PhD · 801-262-3592 · david.rabiger@biofiredefense.com
Always discuss trial participation with your own doctor first.
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| George Washington University | Washington D.C., District of Columbia, United States | Recruiting |
| Tampa General Hospital | Tampa, Florida, United States | Not Yet Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| Wake Forest University Health Sciences | Winston-Salem, North Carolina, United States | Not Yet Recruiting |
| University of Texas Medical Branch | Galveston, Texas, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07221097